Swiss firm Novartis stops Hydroxychloroquine trial


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ swiss-firm-novartis-stops-hydroxychloroquine-trial
Novartis has decided to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrolment challenges

Swiss pharmaceuticals goliath Novartis has chosen to stop a clinical preliminary of hydroxychloroquine as a treatment for COVID-19, referring to issues in enlisting enough patients for the investigation of the questionable medication.

"Novartis has settled on the choice to stop and end its supported HCQ clinical preliminary for COVID-19 because of intense enrolment challenges that have made preliminary consummation infeasible," the organization said in an announcement late Friday.

This issue "made it impossible that the clinical group will have the option to gather important information in a sensible time period," it said.

"No wellbeing issues have been accounted for, and there are no ends on viability from the investigation."

Hydroxychloroquine and its related compound chloroquine have customarily been utilized to treat intestinal sickness and with a referred to against viral potential was viewed as a potential treatment at the beginning of the pandemic.

In spite of perceived genuine reactions, numerous conspicuous figures, including US President Donald Trump, touted it generally as a COVID-19 treatment when there is no antibody for the infection and other conceivably compelling medications are just barely starting to be distinguished.

In April, Novartis said it would support a Phase III clinical preliminary of around 440 patients in the US utilizing hydroxychloroquine to treat patients hospitalized with COVID-19 in concurrence with the US Food and Drug Administration (FDA).

However, prior this month, the US specialists suspended its utilization, and this week the World Health Organization said it was suspending its preliminaries of hydroxychloroquine since it demonstrated no capacity to decrease death rates.

Tags : #Swiss #Novartis #HCQ

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026